ebm prof darwin 4. prognosis ebm_dr kuntjoro.ppt
TRANSCRIPT
![Page 1: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/1.jpg)
AppraisingPrognostic Study
![Page 2: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/2.jpg)
Introduction - Prognosis• Important phase of a disease progression of
a disease. • Patient’s, doctor’s, insurance’s concern • Prognosis: the prediction of the future course
of events following the onset of disease. – can include death, complications,
remission/recurrence, morbidity, disability and social or occupational function.
![Page 3: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/3.jpg)
Introduction - Prognosis
• Possible outcomes of a disease and the frequency with which they can be expected to occur.– Natural history: the evolution of disease
without medical intervention. – Clinical course: the evolution of disease in
response to medical intervention.
![Page 4: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/4.jpg)
Natural History Studies• Degree to which natural history can be studied
depends on the medical system (Scandinavia) and the type of disease (rare, high risk).
• The natural history of some diseases can be studied because:
• remain unrecognized (i.e., asymptomatic) e.g., anemia, hypertension.
• considered “normal” discomforts e.g., arthritis, mild depression.
![Page 5: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/5.jpg)
Natural History Studies
• Natural history studies permit the development of rational strategies for:– early detection of disease
• e.g., Invasive Cervical CA.
– treatment of disease • e.g. Diabetes
![Page 6: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/6.jpg)
Prognosis
Patients at risk of target eventPatients at risk of target event
Prognosticfactor
Prognosticfactor TimeTime
Suffer targetoutcome
Suffer targetoutcome
Do not suffertarget outcome
?
?
![Page 7: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/7.jpg)
1. Was a defined, representative sample of patients assembled at a common (usually early) point in the course of their disease?
2. Was the follow-up of the study patients sufficiently long and complete?
3. Were objective outcome criteria applied in a blind fashion?
4. If subgroups with different prognoses are identified, was there adjustment for important prognostic factors and validation in an independent “test set” patients?
A. ARE THE RESULTS OF THIS A. ARE THE RESULTS OF THIS PROGNOSIS STUDY VALID? PROGNOSIS STUDY VALID? A. ARE THE RESULTS OF THIS A. ARE THE RESULTS OF THIS PROGNOSIS STUDY VALID? PROGNOSIS STUDY VALID?
![Page 8: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/8.jpg)
• How well defined the individuals in the study – criteria - representative of the underlying population. – inclusion, exclusion – sampling method
• similar, well-defined point in the course of their disease cohort
A.1. Was a defined, representative sample of patients assembled at a common (usually early) point in the course of their disease?
A.1. Was a defined, representative sample of patients assembled at a common (usually early) point in the course of their disease?
![Page 9: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/9.jpg)
A.2. Was follow-up sufficiently long and complete? A.2. Was follow-up sufficiently long and complete?
• Ideal follow-up period – Until EVERY patient recovers or has one of the other
outcomes of interest, – Until the elapsed time of observation is of clinical interest to
clinicians or patients. • Short follow up time too few study patients with outcome of
interest little information of use to patient • Loss to follow up influence the estimate of the risk of the
outcome validity?. – Patients are too ill (or too well); Die; Move, etc
• Most journals require at least 80% follow-up for a prognosis study to be considered valid.
• Best and worst case scenario (sensitivity analysis)
![Page 10: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/10.jpg)
A.3. Were objective outcome criteria applied in a blind fashion?A.3. Were objective outcome criteria applied in a blind fashion?
• Investigators making judgments about clinical outcomes are kept “blind” to subjects’ clinical characteristics and prognostic factors.
• Minimize measurement bias!
![Page 11: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/11.jpg)
Measurement bias• Measurement bias can be minimized by:
– ensuring observers are blinded to the exposure status of the patients.
– using careful criteria (definitions) for all outcome events.
– apply equally rigorous efforts to ascertain all events in both exposure groups.
![Page 12: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/12.jpg)
• Prognostic factors: factors associated with a particular outcome among disease subjects. Can predict good or bad outcome
• Need not necessarily cause the outcome, just be associated with them strongly enough to predict their development – examples includes age, co-morbidities, tumor size, severity
of disease etc. – often different from disease risk factors e.g., BMI and pre-
menopausal breast CA.
A.4. If subgroups with different prognoses are identified, was there adjustment for important prognostic factors and validation in an independent “test set” patients?
A.4. If subgroups with different prognoses are identified, was there adjustment for important prognostic factors and validation in an independent “test set” patients?
![Page 13: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/13.jpg)
• Risk factors – distinct from prognostic factors, – include lifestyle behaviors and environmental exposures
that are associated with the development of a target disorder.
– Ex: smoking = important risk factor for developing lung cancer, but tumor stage is the most important prognostic factor in individuals who have lung cancer.
A.4. If subgroups with different prognoses are identified, was there adjustment for important prognostic factors and validation in an independent “test set” patients?
A.4. If subgroups with different prognoses are identified, was there adjustment for important prognostic factors and validation in an independent “test set” patients?
![Page 14: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/14.jpg)
Bias in Follow-up Studies A. Selection or Confounding Bias
1. Assembly or susceptibility bias: when exposed and non-exposed groups differ other than by the prognostic factors under study, and the extraneous factor affects the outcome of the study.
• Examples: – differences in starting point of disease (survival cohort)– differences in stage or extent of disease, co-morbidities, prior
treatment, age, gender, or race.
![Page 15: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/15.jpg)
Bias in Follow-up StudiesA. Selection or Confounding Bias
2. Migration bias: • patients drop out of the study (lost-to-follow-up).
usually subjects drop out because of a valid reason e.g., died, recovery, side effects or disinterest.
• these factors are often related to prognosis. • asses extent of bias by using a best/worst case
analysis. • patients can also cross-over from one exposure group
to another • if cross-over occurs at random = non-differential
misclassification of exposure
![Page 16: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/16.jpg)
Bias in Follow-up StudiesA. Selection or Confounding Bias
3. Generalizability bias• related to the selective referral of
patients to tertiary (academic) medical centers.
• highly selected patient pool have different clinical spectrum of disease.
• influences generalizability
![Page 17: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/17.jpg)
Survival Cohorts
• Survival cohort (or available patient cohort) studies can be very biased because:– convenience sample of current patients are likely to be at
various stages in the course of their disease.– individuals not accounted for have different experiences
from those included e.g., died soon after trt.
• Not a true inception cohort e.g., retrospective case series.
![Page 18: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/18.jpg)
Surv
ival
Coh
orts
B
ias
True CohortTrue Cohort
Survival CohortSurvival Cohort
ObservedImprovement
TrueImprovement
AssembleCohortN=150
Measure OutcomesImproved = 75Not improved = 75
50% 50%
80% 50%Measure OutcomesImproved = 40Not improved = 10
Assemble patients
BeginFollow-upN = 50
Not ObservedN = 100
Dropouts:Improved = 35Not improved = 65
![Page 19: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/19.jpg)
II. Bias in Follow-Up Studies
B. Measurement bias– Measurement (or assessment) bias occurs when
one group has a higher (or lower) probability of having their outcome measured or detected.
• likely for softer outcomes – side effects, mild disabilities, subclinical disease or – the specific cause of death.
![Page 20: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/20.jpg)
B. Are the results of this study important?B. Are the results of this study important?
1. How likely are the outcomes over time?
2. How precise is this prognostic estimate?
![Page 21: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/21.jpg)
B.1. How likely are the outcomes over time? B.1. How likely are the outcomes over time?
• % of outcome of interest at a particular point in time (1 or 5 year survival rates)
• Median time to the outcome (e.g. the length of follow-up by which 50% of patients have died)
• Event curves (e.g. survival curves) that illustrate, at each point in time, the proportion of the original study sample who have not yet had a specified outcome.
![Page 22: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/22.jpg)
Survival Rate 1 year survivalA. Good
B. 20%
C. 20%
D. 20%
Median survivalA. ?
B. 3 months
C. 9 months
D. 7.5 months
![Page 23: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/23.jpg)
B.2 How precise is this prognostic estimate? B.2 How precise is this prognostic estimate?
• Precision 95% confidence interval– The narrower the confidence interval, the more
precise is the estimate.
• If survival over time is the outcome of interest shorter follow-up periods results in more precision follow up period important to be clinically important
![Page 24: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/24.jpg)
C. Can we apply this valid, important evidence about prognosis to our patients?
1. Is our patient so different from those in the study that its results cannot apply?
2. Will this evidence make a clinically important impact on our conclusions about what to offer or tell our patient?
![Page 25: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/25.jpg)
Is our patient so different from those in the study that its results cannot apply?Is our patient so different from those in the study that its results cannot apply?
• How well do the study results generalize to the patients in your practice? – Compare patients' important clinical characteristics, – Read the definitions thoroughly – The closer the match between the patient before
you and those in the study, the more confident you can be in applying the study results to that patient.
• For most differences, the answer to this question is “no”, we can use the study results to inform our prognostic conclusions.
![Page 26: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/26.jpg)
C.2 Will this evidence make a clinically important impact on our conclusions about what to offer or tell our patient?
C.2 Will this evidence make a clinically important impact on our conclusions about what to offer or tell our patient?
• Useful for – Initiating or not therapy, – monitoring therapy that has been initiated, – deciding which diagnostic tests to order. – providing patients and families with the
information they want about what the future is likely to hold for them and their illness.
![Page 27: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/27.jpg)
C.2 Will this evidence make a clinically important impact on our conclusions about what to offer or tell our patient?
C.2 Will this evidence make a clinically important impact on our conclusions about what to offer or tell our patient?
• Communicating to patients their likely fate
• Guiding treatment decisions• Comparing outcomes to make
inferences about quality of care
![Page 28: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/28.jpg)
Conclusion• Prognosis study beneficial
– Communicating to patients their likely fate– Guiding treatment decisions– Comparing outcomes to make inferences
about quality of care
![Page 29: EBM Prof Darwin 4. Prognosis EBM_dr Kuntjoro.ppt](https://reader035.vdocument.in/reader035/viewer/2022062308/55cf9043550346703ba476d2/html5/thumbnails/29.jpg)